PSYBF - PsyBio Therapeutics Corp.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.0220 |
| Open | 0.0177 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0156 - 0.0220 |
| 52 Week Range | 0.0120 - 0.1450 |
| Volume | |
| Avg. Volume | 22,615 |
| Market Cap | 2.43M |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Jun 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
NewsfilePsyBio Announces Closing of Third Tranche of Private Placement
Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - April 20, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the third tranche of its previously announced non-brokered private placement offering of uni
NewsfilePsyBio Announces Panel Participation on NextGen Psychedelics at Benzinga Cannabis Capital Conference
Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - April 6, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that PsyBio CEO Evan Levine will be participating on the panel NextGen Psychedelics and conducting one-on-one meetings, at B
- Newsfile
PsyBio Therapeutics Founder Wins Best Pitch at Investment Summit
Prestigious award recognizes innovative company as a leading player in the emerging field of psychedelic medicine Miami, Florida--(Newsfile Corp. - March 13, 2023) - Evan Levine, CEO and Founder of PsyBio Therapeutics, won Best Pitch at Kahner Global's Cannabis & Psychedelics Investment Summit last week. Levine was awarded for his visionary approach to developing next-generation therapies for mental health conditions using cutting-edge research and development methods.The Summit is an annual con
Simply Wall St.A PsyBio Therapeutics Corp. (CVE:PSYB) insider increased their holdings last year
Looking at PsyBio Therapeutics Corp.'s ( CVE:PSYB ) insider transactions over the last year, we can see that insiders...
NewsfilePsyBio Announces Closing of Second Tranche of Private Placement
Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 13, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the second tranche of its previously announced non-brokered private placement offering of
NewsfilePsyBio Announces Appointment of Ian Wisenberg to Board of Directors
Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 10, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused on the discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an indepen
- Newsfile
PsyBio Announces Closing of First Tranche of Private Placement Led by the Chairman and Chief Executive Officer with Participation from the Entire Board of Directors and Management Team and Provides Corporate Update
Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 5, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the first tranche of its previously announced non-brokered private placement offering of un
CNW GroupPsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the filing of three additional U.S. Provisional Patent Applications covering its latest discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen.
CNW GroupPsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by Ps
CNW GroupPsyBio Therapeutics Announces Non-Brokered Private Placement Financing
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused on discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, announces that it intends to complete a non-brokered private placement of up to 20,000,000 units of the Company (each, a "Unit") at an issue price of C$0.05 per Unit for gross proceeds of up to C$1,000,000 (the "Offering").
CNW GroupPsyBio Therapeutics Reports Third Quarter 2022 Financial Results
OXFORD, Ohio and DENVER, Nov. 29, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its unaudited interim financial results for the three and nine month period ended Septe
CNW GroupPsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announces that it has reached an initial agreement with experienced clinical researchers to conduct a clinical trial utilizing PsyBio's proprietary biosynthetic psilocybin product upon obtaining all necessary approv
CNW GroupPsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the formal acceptance by the United States Patent and Trademark Office of its latest U.S. PCT (Non-Provisional) Patent Application.
CNW GroupPsyBio Therapeutics to Present at Upcoming Investor Events in September 2022
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announces that Evan Levine, Chief Executive Officer and Chairman, will present at the following upcoming conferences in September 2022:
CNW GroupPsyBio Therapeutics Reports Second Quarter 2022 Financial Results
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its unaudited interim financial results for the three and six month period ended June 30, 2022.
CNW GroupPsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application
PsyBio Therapeutics Corp. (TSXV: PSYB), (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of data to support the conversion of a previously submitted provisional patent covering the biosynthetic production of methylated tryptamine derivatives including N,N-dimethyltryptamine ("DMT") and
CNW GroupPsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of additional international patent applications in Europe, Africa, and Asia. This brings PsyBio's total number of patent application submissions to twenty, making it one of the most robust p
CNW GroupPsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), announces that it will be hosting its annual general and special meeting of shareholders (the "Meeting") virtually at 11:00 am Eastern Time on Thursday, August 11, 2022, as further detailed in proxy materials being distributed to shareholders, which will be available under the Company's profile on SEDAR at www.sedar.com.
CNW GroupPsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today reported that it has initiated formal process development for commercially scalable, patent pending manufacturing technology expected to enable Good Manufac
CNW GroupPsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its interim financial results for the three month period ended March 31, 2022 and provided shareholders with a corporate upda